evamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial. - Levamisol Trial
- Conditions
- Steroid Sensitive Nephrotic Syndrome (SSNS)MedDRA version: 9.1Level: LLTClassification code 10029172Term: Nephrotic syndrome with unspecified pathological lesion in kidney
- Registration Number
- EUCTR2005-005745-18-BE
- Lead Sponsor
- Emma Children's Hospital-AMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Frequently relapsing idiopathic SSNS with or without steroid dependency
- Age between 2 and 18 years
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- Patient previously treated with Levamisole
- Patients unresponsive to Cyclosporine or MMF
- Nephrotic Syndrome due to specific kidney disease
- Patients presenting with leucopenia, convulsions or with hepatic diseases
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method